These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12243512)

  • 1. Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients.
    Fehm T; Gebauer G; Jäger W
    Breast Cancer Res Treat; 2002 Sep; 75(2):97-106. PubMed ID: 12243512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients.
    Molina R; Jo J; Filella X; Zanón G; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
    Anticancer Res; 1999; 19(4A):2551-5. PubMed ID: 10470193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.
    Molina R; Jo J; Zanón G; Filella X; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
    Br J Cancer; 1996 Oct; 74(7):1126-31. PubMed ID: 8855986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
    Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
    Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein.
    Wu JT; Astill ME; Gagon SD; Bryson L
    J Clin Lab Anal; 1995; 9(3):151-65. PubMed ID: 7541455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
    Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
    Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer.
    Fehm T; Maimonis P; Katalinic A; Jäger WH
    Oncology; 1998; 55(1):33-8. PubMed ID: 9428373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential use of saliva to detect recurrence of disease in women with breast carcinoma.
    Bigler LR; Streckfus CF; Copeland L; Burns R; Dai X; Kuhn M; Martin P; Bigler SA
    J Oral Pathol Med; 2002 Aug; 31(7):421-31. PubMed ID: 12165061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer.
    Baskić D; Ristić P; Matić S; Banković D; Popović S; Arsenijević N
    Biomarkers; 2007; 12(6):657-67. PubMed ID: 17852076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
    Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
    Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse.
    Sugano K; Ushiama M; Fukutomi T; Tsuda H; Kitoh T; Ohkura H
    Int J Cancer; 2000 Jul; 89(4):329-36. PubMed ID: 10956406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy.
    Classen S; Kopp R; Possinger K; Weidenhagen R; Eiermann W; Wilmanns W
    Tumour Biol; 2002; 23(2):70-5. PubMed ID: 12065844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.
    Ali SM; Leitzel K; Chinchilli VM; Engle L; Demers L; Harvey HA; Carney W; Allard JW; Lipton A
    Clin Chem; 2002 Aug; 48(8):1314-20. PubMed ID: 12142389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer.
    Isola JJ; Holli K; Oksa H; Teramoto Y; Kallioniemi OP
    Cancer; 1994 Feb; 73(3):652-8. PubMed ID: 7905363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
    Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
    Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study.
    Streckfus C; Bigler L; Dellinger T; Dai X; Kingman A; Thigpen JT
    Clin Cancer Res; 2000 Jun; 6(6):2363-70. PubMed ID: 10873088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
    Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
    Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients.
    Pichon MF; Hacene K; Guepratte S; Neumann R
    Clin Lab; 2004; 50(3-4):163-70. PubMed ID: 15074470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
    Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J
    Oncology; 1994; 51(6):491-6. PubMed ID: 7970492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.